Pfizer Inc. announced positive results from a phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active ankylosing spondylitis (AS). Tofacitinib is not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback